• New Position Statement From NAMS on Hormone TherapyWhat's new in the 2012 position statement from NAMS? Dr. JoAnn Manson summarizes the key points to help clinicians stay up-to-date.
  Medscape Ob/Gyn, March 2012

More

• Menopausal Hormone Therapy: New Guidance From NAMSWhat are the latest recommendations from NAMS on the use of vaginal hormone therapy? Dr. Andrew Kaunitz highlights the issues of most importance to women's healthcare providers.
  Medscape Ob/Gyn, February 2012

More

• 2012 Hormone Therapy Position Statement From NAMS
  March 2012
• Racial Differences and CVD in Women Going Through Menopause
  February 2012
• Is Smoking Associated With Increased Risk of Early Menopause?
  February 2012
• The Perimenopausal Atherosclerosis Transition
  January 2012
• Vulvovaginal Atrophy and Sexual Dysfunction in Postmenopause
  January 2012

More

• Body Composition and Age
  March 2012
• Estrogens-B and Nocturnal Vasomotor Symptoms
  February 2012
• Breast Tenderness and Breast Cancer Risk With ET/EPT
  January 2012
• Ovarian Disruption and CVD
  November 2011
• Triptorelin Effect on Chemotherapy-induced Early Menopause
  October 2011

Join NAMS and receive the First to Know e-newsletter every month.

More

• Migraines and Perimenopause
  October 2011
• Breast Cancer and Acupuncture
  May 2011
• HT in Managing Depression in a Patient Using SSRIs
  December 2010
• Prolapse Management in Patients With Incontinence and Hysterectomy
  October 2010
• Alzheimer's: Diagnostic Testing and Counseling About Memory
  January 2010

Join NAMS and receive the Menopause e-Consult quarterly.

More

• NAMS: The 2012 Hormone Therapy Position Statement
  March 2012
• NAMS Position Statement: Management of Osteoporosis
  June 2011
• NAMS Position Statement: Estrogen and Progestogen Use
  June 2011
• NAMS on Local Estrogen for Vaginal Atrophy
  May 2008

More